Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

219.16 +0.12 (+0.05%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
89 90 Next >
Trouble-Proof Dividend Darlings: 7 Stocks That Keep Paying No Matter What
With economic conditions presenting a question mark for the consumer economy, these dividend stocks may shine brightly. 
Via InvestorPlace
Topics Economy
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
The company tested its psoriatic arthritis drug over 24 weeks against Humira. 
Via Investor's Business Daily
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors. 
Via Benzinga
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
There are some great companies at attractive prices in the lucrative pharmaceutical space. 
Via The Motley Fool
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. 
Via InvestorPlace
Is AbbVie Stock a Buy Now?
Some would say the growth story is over, but that view might be a bit myopic. 
Via The Motley Fool
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
 
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Friday Morning
Via Investor Brand Network
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
These businesses can pack a punch in your portfolio over the long run. 
Via The Motley Fool
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates
These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
The Top 7 Dividend Stocks to Buy in March 2024
Bet on these top dividend stocks to buy for a resilient income flow and steady market gains, offering excellent balance. 
Via InvestorPlace
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Secure Your Future: 7 Dividend Kings with Solid Growth Potential
Here are seven dividend kings that manage to deliver market-beating stock price growth in addition to their reliable, growing dividends. 
Via InvestorPlace
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
Better Dividend Growth Stock: AbbVie or Amgen?
A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy. 
Via The Motley Fool
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
From Healis Therapeutics
Via GlobeNewswire
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade
These stocks don't offer the highest yields, but their payouts are growing fast. 
Via The Motley Fool
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. 
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
These stocks check off multiple boxes for investors. 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable. 
Via The Motley Fool
5 Forever Dividend Stocks to Build Your Portfolio
These five stocks are high quality and reliable. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy Right Now
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
Via The Motley Fool
3 Cash Cows to Boost Your Confidence During the February Chill
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.